2019 American Transplant Congress
Reduction In Early Readmission In Kidney Recipients – Outcomes At One Year With Standardized Intensive Follow Up
Glickman Urological and Kidney Institute CCF, Cleveland, OH
*Purpose: Kidney transplant recipients often experience frequent ED visits and high early hospital readmission (EHR) rates (within 30 days). We sought to decrease our preventable…2019 American Transplant Congress
Predictors of Response to Intravenous Immunoglobulin for Treatment of Polyoma Nephropathy
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: BK nephropathy is an important cause of allograft dysfunction or loss. IVIg is hypothesized to be effective by providing passive immunity to BK virus…2019 American Transplant Congress
A Single Measurement of Torque Teno Virus Helps to Predict Mortality in Renal Transplant Patients
*Purpose: Multiple studies have used longitudinal Torque Teno Virus (TTV) measurements to assess the immune status after transplantation. Longitudinal measurements generally show a TTV load…2019 American Transplant Congress
Ultra-Short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Two recent pilot trials have shown that transplanting hepatitis C (HCV) viremic kidneys in to HCV negative recipients is feasible. These trials used 12…2019 American Transplant Congress
APRIL-/-/BLyS-/- Deplete Antibody Secreting Cells and Alloantibody Production in Sensitized Antibody Mediated Rejection Model
University of Wisconsin, Madison, WI
*Purpose: Antibody mediated rejection (AMR) is a major cause of kidney allograft failure. APRIL (A proliferation inducing ligand) and BLyS (B Lymphocyte Stimulator) are two…2019 American Transplant Congress
External Validation of Donor-Derived Cell-Free DNA to Detect Rejection in Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA; Allosure®, CareDx) became Medicare-reimbursable in the United States in October, 2017 for the detection of rejection in kidney transplant recipients…2019 American Transplant Congress
Subclinical Rejection by Biopsy or Gene Expression Profile Predicts Long Term Kidney Function in Patients in the CTOT08 Trial
*Purpose: The CTOT08 trial showed that either histological subAR or positive gene expression profile (GEP) in the blood associated with histological subAR correlated with a…2019 American Transplant Congress
The Impact of Calcineurin Inhibitors on De Novo DSA in Primary Kidney Transplantation
Nagoya Daini Red Cross Hospital, Nagoya Aichi, Japan
*Purpose: De novo DSA was demonstrated as a cause of chronic AMR, leading to worse graft survival. New strategies to treat chronic AMR have been…2019 American Transplant Congress
Transplantation of the Highly Sensitized Renal Transplant Candidate in the Post-KAS Era: Who is Left Out?
*Purpose: Highly sensitized kidney transplant candidates are given high priority under the new kidney allocation system (KAS), but it is unclear if all sensitized candidates…2019 American Transplant Congress
Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation
Emory University School of Medicine, Atlanta, GA
*Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…
- « Previous Page
- 1
- …
- 210
- 211
- 212
- 213
- 214
- …
- 531
- Next Page »